Skip to content

Misoprostol plus intramuscular hyoscine-N-butylbromide versus misoprostol plus placebo for cervical ripening among term parturients at the Niger Delta University Teaching Hospital Okolobiri: A randomised Control Trial.

Misoprostol plus intramuscular hyoscine-N-butylbromide versus misoprostol plus placebo for cervical ripening among term parturients at the Niger Delta University Teaching Hospital Okolobiri: A randomised Control Trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
PACTR
Registry ID
PACTR202605690422756
Enrollment
160
Registered
2026-05-18
Start date
2026-02-25
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Fertility-female

Interventions

Misoprostol and hyoscine butyl bromide
misoprostol and placebo group

Sponsors

NINABAI NAPOLEON OFURUMA
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Term pregnant women (37 - 41 weeks + 6days gestation) 2.Singleton gestation 3.Cephalic presenting fetuses 4.Intrauterine foetal death at term 5.Intact foetal membranes 6.Bishop Scores =5 7.Medical disorders of pregnancy

Exclusion criteria

Exclusion criteria: 1.Previous uterine scar (Myomectomy or CS, previous uterine rupture, metroplasty, hysterotomy) 2.Preterm or post-term pregnancies 3.Premature rupture of foetal membranes 4.Congenital fetal anomalies 5.Contraindication to vaginal delivery Known history of allergy to misoprostol

Design outcomes

Primary

MeasureTime frame
the duration of cervical ripening

Secondary

MeasureTime frame
duration of first and second stages of labour, those requiring oxytocin, route of delivery, indication for CS if CS was done, APGAR SCORES, EBL, admission to SCBU, side effects of misoprostol and hyoscine-N-butylbromide

Countries

Nigeria

Contacts

Public ContactNINABAI NAPOLEON OFURUMA

Senior Registrar

drninabai@gmail.com+2348064128579

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026